A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin

Archives of Internal Medicine

Volumn 163, Issue 8, 2003, Pages 936-943

  Van Walraven, Carl ^a,b   Hart, Robert G ^c   Wells, George A ^a   Petersen, Palle ^d   Koudstaal, Peter J ^g   Gullov, Annette L ^e   Hellemons, Beppie S P ^h   Koefed, Birgitte G ^f   Laupacis, Andreas ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Rigshospitalet   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f Sundhedsstyrelsen   (Denmark)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT;

AGED; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; HEALTH SURVEY; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HEALTH STATUS INDICATORS; HUMANS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 0242684413     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.8.936     Document Type: Article

References (50)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131:492-501.
3. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Anti-thrombotic therapy in atrial fibrillation. Chest 2001;119(1, suppl): 194S-206S.
4. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154: 2254]. Arch Intern Med. 1994;154:1449-1457.
6. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thrombo-embolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157.
7. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-1277.
8. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW, for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30:1223-1229.
9. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864-2870.
10. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
11. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001;135:393-400.
12. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124:970-979.
13. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-152.
14. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
15. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thrombo-embolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
16. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
17. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319: 958-964.
18. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84: 527-539.
19. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
21. Redelmeier DA, Lustig AL. Prognostic indices in clinical practice. JAMA. 2001; 285:3024-3025.
22. Stiell IG, McKnight RD, Greenberg GH, et al. Implementation of the Ottawa ankle rules. JAMA. 1994;271:827-832.
23. Stiell IG, Wells G, Laupacis A, et al. Multicentre trial to introduce the Ottawa ankle rules for use of radiography in acute ankle injuries. BMJ. 1995;311:594-597.
24. Stiell IG, Wells GA, Hoag RH, et al. Implementation of the Ottawa Knee Rule for the use of radiography in acute knee injuries. JAMA. 1997;278:2075-2079.
25. van Walraven C, Mahon JL, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample-size calculation. J Clin Epidemiol. 1999;52:717-723.
26. Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995;15:152-157.
27. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ. 1994;309:761-764.
28. Hux JE, Levinton CM, Naylor CD. Prescribing propensity: influence of life-expectancy gains and drug costs. J Gen Intern Med. 1994;9:195-201.
29. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med. 1993;8:543-548.
30. Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992;92:121-124.
31. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992;117:916-921.
32. Zhang Z, Singer B. A Practical Guide to Tree Construction: Recursive Partitioning in the Health Sciences. New York, NY: Springer Publishing Co Inc; 1999:7-16.
33. SAS Guide to Macro Processing. 2nd ed. Cary, NC: SAS Institute; 1990.
34. Greenland S, Rothman KJ. Introduction to categorical statistics. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:253-280.
35. Hirsch RP, Riegelman RK. Statistical First Aid. Interpretation of Health Research Data. Malden, Mass: Blackwell Publishers; 1992:40-64.
36. Hennekens CH, Buring JE. Measures of disease frequency and association. In: Mayrent SL, ed. Epidemiology in Medicine. Boston, Mass: Little Brown & Co Inc; 1987:54-93.
37. Lindenstrom E, Boysen G, Nyboe J, Appleyard M. Stroke incidence in Copenhagen, 1976-1988. Stroke. 1992;23:28-32.
38. Hollander M, Koudstaal PJ, Bots ML, Hofman A, Breteler MM. Incidence, risk and case fatality of stroke in the elderly: the Rotterdam Study. J Neurol Neurosurg Psychiatry. In press.
39. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population-based study. Ann Intern Med. 1999;130:14-22.
40. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules: applications and methodological standards. N Engl J Med. 1985;313:793-799.
41. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA. 1997;277:488-494.
42. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults: the Cardiovascular Health Study. Stroke. 1996;27:1479-1486.
43. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
44. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
45. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibriallation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
46. Bonita R, Broad JB, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91. Lancet. 1993;342:1470-1473.
47. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke. 1992;23:1551-1555.
48. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-380.
49. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
50. Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart. 1999;82:539-540.